Analyst Julian Harrison of BTIG maintained a Buy rating on Theravance Biopharma, retaining the price target of $40.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Julian Harrison has given his Buy rating due to a combination of factors that highlight the potential of Theravance Biopharma’s drug, ampreloxetine, in the treatment of neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA). The drug’s unique attributes, such as improved dosing and lack of worsening supine hypertension, make it a promising candidate in a market with no current treatments specifically approved for this condition.
Harrison also points out that the upcoming Phase 3 CYPRESS trial, expected in the first quarter of 2026, could further solidify ampreloxetine’s market position if successful. With a significant unmet need recognized by healthcare professionals and a large target market both in the U.S. and internationally, the commercial opportunity for ampreloxetine is substantial. Additionally, the drug’s potential to capture market share is supported by strong interest from neurologists and cardiologists, pending positive trial results and regulatory approval.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.
TBPH’s price has also changed dramatically for the past six months – from $10.950 to $17.810, which is a 62.65% increase.